{"id":"NCT01668784","sponsor":"Bristol-Myers Squibb","briefTitle":"Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)","officialTitle":"A Randomized, Open-Label, Phase 3 Study of Nivolumab (BMS-936558) vs. Everolimus in Subjects With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-10-09","primaryCompletion":"2015-05-06","completion":"2021-07-19","firstPosted":"2012-08-20","resultsPosted":"2016-04-29","lastUpdate":"2022-08-09"},"enrollment":821,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma"],"interventions":[{"type":"BIOLOGICAL","name":"Nivolumab","otherNames":["BMS-936558"]},{"type":"DRUG","name":"Everolimus","otherNames":["Afinitor"]}],"arms":[{"label":"Arm 1: Nivolumab","type":"EXPERIMENTAL"},{"label":"Arm 2: Everolimus","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of the study is to compare the clinical benefit, as measured by duration of overall survival, of Nivolumab vs. Everolimus in subjects with advanced or metastatic clear-cell renal cell carcinoma who have received prior anti-angiogenic therapy","primaryOutcome":{"measure":"Overall Survival (OS) at Primary Endpoint","timeFrame":"Randomization until 398 deaths, up to May 2015 (approximately 30 months)","effectByArm":[{"arm":"Nivolumab","deltaMin":25,"sd":null},{"arm":"Everolimus","deltaMin":19.55,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0018"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":6},"locations":{"siteCount":168,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Czechia","Denmark","Finland","France","Germany","Greece","Ireland","Israel","Italy","Japan","Norway","Poland","Romania","Russia","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["33428174","31992108","31272883","30215677","28410865","28262413","27283863","26406148"],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","https://www.bmsstudyconnect.com/s/US/English/USenHome","https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":248,"n":406},"commonTop":["Fatigue","Cough","Nausea","Diarrhoea","Decreased appetite"]}}